ProfileGDS5678 / 1436119_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 56% 56% 56% 57% 55% 56% 56% 59% 56% 56% 57% 66% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3998354
GSM967853U87-EV human glioblastoma xenograft - Control 23.427456
GSM967854U87-EV human glioblastoma xenograft - Control 33.3943256
GSM967855U87-EV human glioblastoma xenograft - Control 43.3570256
GSM967856U87-EV human glioblastoma xenograft - Control 53.4022657
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4746155
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5210756
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3941556
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5180759
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3897756
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4031556
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4309357
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9700566
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.407756